Immuneering jumps after positive trial data for pancreatic cancer therapy

Shares of therapy developer Immuneering IMRX.O rise 38.5% to $12.78 in extended trade

Company says its therapy, IMM-1-104, showed an overall response rate of 86% in combination with gemcitabine during a mid-stage trial over 9 months of treatment in patients with pancreatic cancer

Co expects regulatory feedback on the trial plans in Q4

Separately, IMRX says that Sanofi SASY.PA has agreed to purchase $25 million of its shares in a private placement transaction that is expected to close concurrently with the offering

Company intends to use the net proceeds to advance the preclinical and clinical development of its product candidates

As of last close, stock more than tripled YTD